CHMP makes recommendations on Iclusig label
This article was originally published in Scrip
Executive Summary
The EU's CHMP has outlined its recommended changes to the labelling for Ariad Pharmaceutical's troubled leukemia treatment, Iclusig (ponatinib), following its latest meeting on 18-21 November.